Ensaios Clínicos

Neste separador, poderá encontrar ensaios clínicos de fase II e III na área da Hepatologia,  em fase de recrutamento, a decorrer em Portugal.

Para consultar informação detalhada sobre cada ensaio, clique sobre o link correspondente. Os contactos dos investigadores nacionais podem ser encontrados em “Locations and contact points”.

Fonte: https://euclinicaltrials.eu/

Doenças genéticas e metabólicas

A Randomized, Double-blind, Placebo-Controlled, Phase 3 Study to Evaluate the Efficacy and Safety of Fazirsiran in the Treatment of Alpha-1 Antitrypsin Deficiency–Associated Liver Disease With METAVIR Stage F2 to F4 Fibrosis

EUCT number:2022-501943-34-00

An Open-Label Extension Study of Fazirsiran

EUCT number:2023-503497-21-00

Study to learn about the safety of fazirsiran and if it can help people with alpha-1 antitrypsin liver disease with mild liver scarring (fibrosis)

EUCT number:2023-504198-19-00

A study to understand the safety and the effects of a virus that transfers a modified protein responsible for copper metabolism (copper-transporting P-type adenosine triphosphatase, ATP7B) in adults with Wilson disease.

EUCT number:2022-502873-40-00

Neoplasias hepáticas

Phase 2 Study of Futibatinib 20 mg and 16 mg in Patients with Advanced Cholangiocarcinoma with FGFR2 Fusions or Rearrangements (FOENIX-CCA4)

EUCT number: 2023-503665-39-00

An open-label randomized trial of the efficacy and safety of zanidatamab with standard-of-care therapy against standard of-care therapy alone for advanced HER2 positive biliary tract cancer

EUCT number: 2023-508219-21-00

A Clinical Trial of Pembrolizumab (MK-3475) Evaluating Predictive Biomarkers in Subjects with Advanced Solid Tumors (KEYNOTE-158)

EUCT number: 2022-501253-37-00

Doenças hepáticas autoimunes

A study to assess safety and efficacy of Elafibranor in Adult Participants with Primary Sclerosing Cholangitis (PSC)

EUCT number:2024-511370-72-00